Amerise BioScie

Why is Amerise Biosciences Ltd falling/rising?

As of 17-Jul, Amerise Biosciences Ltd's stock price is 0.89, down 4.3% due to a decline in investor participation and consecutive losses. Despite this short-term downturn, the stock has increased 45.90% year-to-date and 17.11% over the past month.

As of 17-Jul, Amerise Biosciences Ltd's stock price is currently at 0.89, reflecting a decrease of 0.04, or 4.3%. This decline can be attributed to several factors. The stock has underperformed its sector by 4.69% today and has been on a consecutive downward trend, losing 6.32% over the last two days. Additionally, there has been a notable decrease in investor participation, with delivery volume dropping by 14.77% compared to the five-day average. <BR><BR>Despite these short-term challenges, it is important to note that the stock has shown strong performance over longer periods, with a year-to-date increase of 45.90% and a one-month increase of 17.11%. However, the current price movement indicates a negative sentiment in the short term, influenced by the recent consecutive falls and reduced trading activity.

Which are the latest news on Amerise BioScie?

What does Amerise BioScie do?

Amerise Biosciences Ltd is a micro-cap manufacturer in the industrial plastic products sector, originally incorporated in 1984 and rebranded in 2021. As of March 2026, it reported no net sales or profit, with a market cap of INR 4 Cr and a P/E ratio of 228.00.

Overview: <BR>Amerise Biosciences Ltd is a specialized manufacturer operating in the Plastic Products - Industrial industry within the micro-cap market segment.<BR><BR>History: <BR>The company was initially incorporated in 1984 as 'Amstar Laminates Limited'. It underwent several name changes, first to Amardeep Industries Limited in 2002 and then to Amerise Biosciences Limited in August 2021. The latest reported quarter for sales and profit is March 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: N/A <BR>Most recent Net Profit: 0 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 4 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 228.00 <BR>Industry P/E: 20 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.00 <BR>Return on Equity: 0.38% <BR>Price-to-Book: 0.84<BR><BR>Contact Details: <BR>Address: PO5-02D 5th Floor Tower A WTC, Gift City Gandhinagar Gujarat : 382355 <BR>Email: amradeepindustries@gmail.com <BR>Website: http://www.amradeepindustries.quest

How big is Amerise BioScie?

As of 10th June, Amerise Biosciences Ltd has a market capitalization of 4.00 Cr, with reported Net Sales of 0.00 Cr and a Net Profit of 0.02 Cr in the latest four quarters. The balance sheet for March 2025 shows Shareholder's Funds of 5.38 Cr and Total Assets of 8.46 Cr.

As of 10th June, the company name is Amerise Biosciences Ltd, with a market capitalization of 4.00 Cr, categorized as a Micro Cap.<BR><BR>In the latest four quarters, the company reported Net Sales of 0.00 Cr and a Net Profit of 0.02 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, showing Shareholder's Funds of 5.38 Cr and Total Assets of 8.46 Cr.

Who are in the management team of Amerise BioScie?

The management team of Amerise BioScie includes Manisha Maneklal Patel (Independent Director), Dineshkumar Tribhovanbhai Rathod (Whole-time Director), Minal Lakhlani (Company Secretary & Compliance Officer), and Niraj Vaghela (Independent Director).

The management team of Amerise BioScie includes the following individuals:<BR><BR>1. **Manisha Maneklal Patel** - Independent Director<BR>2. **Dineshkumar Tribhovanbhai Rathod** - Whole-time Director<BR>3. **Minal Lakhlani** - Company Secretary & Compliance Officer<BR>4. **Niraj Vaghela** - Independent Director<BR><BR>If you need more details about their roles or the company, feel free to ask!

Who are the peers of the Amerise BioScie?

Amerise BioScie's peers include Aik Pipes & Poly, Tijaria Polypipe, Ashish Polyplast, Polymac Thermof., Arcee Industries, Bloom Dekor, Integ. Thermopl., and Krishna Fil. Ind. Amerise BioScie shows excellent growth and capital structure, while its 1-year return of -21.59% is better than Aik Pipes & Poly's -66.70% but worse than Arcee Industries' 126.67%.

Peers: The peers of Amerise BioScie are Aik Pipes & Poly, Tijaria Polypipe, Ashish Polyplast, Polymac Thermof., Arcee Industries, Bloom Dekor, Integ. Thermopl., and Krishna Fil. Ind.<BR><BR>Quality Snapshot: Good management risk is observed at Aik Pipes & Poly, while Below Average management risk is found at Ashish Polyplast, Polymac Thermof., Arcee Industries, and the rest. Excellent growth is noted at Amerise BioScie, while Below Average growth is seen at Aik Pipes & Poly, Ashish Polyplast, Polymac Thermof., Arcee Industries, Integ. Thermopl., and the rest. Excellent capital structure is present at Amerise BioScie, while Good capital structure is found at Ashish Polyplast, and Below Average capital structure is observed at Aik Pipes & Poly, Polymac Thermof., Arcee Industries, Integ. Thermopl., and the rest.<BR><BR>Return Snapshot: Arcee Industries has the highest 1-year return at 126.67%, while Aik Pipes & Poly has the lowest at -66.70%. Amerise BioScie's 1-year return of -21.59% is better than Aik Pipes & Poly but worse than Arcee Industries. Additionally, Aik Pipes & Poly, Tijaria Polypipe, Ashish Polyplast, Polymac Thermof., and Integ. Thermopl. have negative six-month returns.

When is the next results date for Amerise Biosciences Ltd?

The next results date for Amerise Biosciences Ltd is May 5, 2026.

The next results date for Amerise Biosciences Ltd is scheduled for May 5, 2026.

How has been the historical performance of Amerise BioScie?

Amerise BioScie has shown minimal revenue generation, with net sales at zero from March 2020 to March 2025, and a significant decline in operating income from 9.01 crore in March 2022 to 0.19 crore in March 2025. While expenditures decreased and cash flow turned positive in March 2025, overall profitability remains weak, with profit after tax at only 0.01 crore.

Answer:<BR>The historical performance of Amerise BioScie shows a trend of minimal activity and fluctuating financial metrics over the years, with net sales consistently at zero from March 2020 to March 2025. Other operating income peaked at 9.01 crore in March 2022 but has since declined to 0.19 crore in March 2025. Total operating income followed a similar pattern, dropping from 9.01 crore in March 2022 to 0.19 crore in March 2025. The company reported total expenditure excluding depreciation of 0.18 crore in March 2025, which is significantly lower than the 9.03 crore recorded in March 2022. Operating profit (PBDIT) showed a recovery to 0.01 crore in March 2025 from a loss of 0.34 crore in March 2021, but overall profitability remains weak, with profit after tax at 0.01 crore in March 2025 compared to a profit of 0.55 crore in March 2022. The balance sheet reflects total liabilities of 8.46 crore in March 2025, up from 5.39 crore in March 2024, while total assets also increased to 8.46 crore in March 2025 from 5.39 crore in March 2024. Cash flow from operating activities was positive at 3.00 crore in March 2025, contrasting with previous years where cash flow was non-existent.<BR><BR>Breakdown:<BR>Amerise BioScie's financial history indicates a lack of revenue generation, with net sales remaining at zero from March 2020 to March 2025. The company experienced a significant drop in other operating income from a high of 9.01 crore in March 2022 to just 0.19 crore in March 2025, leading to a total operating income that also fell sharply. Expenditures were notably high in March 2022 but have since decreased, resulting in a slight operating profit in March 2025. Despite this, the company has struggled to maintain profitability, with profit after tax only reaching 0.01 crore in March 2025. The balance sheet shows a rise in total liabilities and assets, indicating some growth, while cash flow from operating activities turned positive in March 2025, marking a potential turning point for the company.

Who are the top shareholders of the Amerise BioScie?

The top shareholders of Amerise BioScie are mainly individual investors, holding 72.09% of the shares, with Amrapali Industries Limited as the largest public shareholder at 4.4%. There are no institutional investors or pledged promoter holdings.

The top shareholders of Amerise BioScie are primarily individual investors, who hold a significant 72.09% of the shares. Among the public shareholders, Amrapali Industries Limited stands out with a holding of 4.4%. There are no institutional shareholders, mutual funds, or foreign institutional investors involved in the company's shareholding structure. Additionally, there are no pledged promoter holdings or a specific promoter with the highest stake.

Is Amerise BioScie overvalued or undervalued?

As of May 20, 2025, Amerise Biosciences Ltd. is considered very expensive and overvalued, with a PE ratio of 5.75, an EV to EBITDA ratio of 5.73, and a significant disparity in earnings growth expectations, despite a 46.67% return over the past year compared to the Sensex's 7.55%, but a long-term decline of -85.26% over 10 years versus the Sensex's 211.47%.

As of 20 May 2025, the valuation grade for Amerise Biosciences Ltd. has moved from risky to very expensive. The company is currently considered overvalued. Key ratios include a PE ratio of 5.75, an EV to EBITDA ratio of 5.73, and a PEG ratio of 0.05, which indicates a significant disparity between its earnings growth expectations and its current price.<BR><BR>In comparison to its peers, Amerise Biosciences Ltd. has a similar PE ratio to its closest competitor, but both are categorized as very expensive. Notably, the company's return over the past year stands at 46.67%, significantly outperforming the Sensex's return of 7.55% in the same period. However, the long-term performance shows a decline, with a 10-year return of -85.26% compared to the Sensex's 211.47%, reinforcing the perception of overvaluation in the current market context.

What is the technical trend for Amerise BioScie?

As of May 12, 2025, Amerise BioScie shows a mildly bearish trend with mixed signals from various indicators, suggesting weak current momentum but some potential for recovery in the longer term.

As of 12 May 2025, the technical trend for Amerise BioScie has changed from bearish to mildly bearish. The weekly MACD remains bearish, while the monthly MACD is mildly bullish, indicating mixed signals across time frames. The daily moving averages are mildly bearish, and the weekly Bollinger Bands also reflect a mildly bearish stance. The KST shows bearish momentum on the weekly chart but is bullish on the monthly chart. Overall, the indicators suggest a mildly bearish sentiment with some potential for recovery in the longer term, but current momentum is weak.

Has Amerise BioScie declared dividend?

No Dividend History Available